Vicore Pharma Holding AB’s Schedule 13G reports that HBM Healthcare Investments (Cayman) Ltd. may be deemed beneficial owner of 22,505,819 Common Shares, approximately 8% of the class, based on 281,644,509 Common Shares outstanding as of September 30, 2026. HBM reports sole voting and dispositive power over 22,505,819 shares and no shared power. It reported 22,687,752 shares and approximately 8.1% as of June 30, 2026, based on 281,525,593 shares outstanding.
Voting and investment power over HBM’s shares is exercised by its board. The listed board members are Jean-Marc LeSieur, Managing Director, Richard H. Coles, Sophia Harris, Dr. Andreas Wicki, Mark Kronenfeld, M.D., and Richard Paul Woodhouse; none has individual voting or investment power.
Vicore Pharma Holding AB reported that 117,737 share awards in Board LTIP 2023, Board LTIP 2024 and Board RSU 2025 were exercised, followed by delivery of 118,916 shares to participants. Outstanding shares and votes each increased by 118,916. As of September 30, 2026, the company had 281,644,509 registered shares and votes.
Vicore Pharma Holding AB (VCRE) reported second-quarter 2026 results as a clinical-stage company advancing its ATRAG pipeline, led by buloxibutid for idiopathic pulmonary fibrosis. Enrollment in the global 52-week Phase 2b ASPIRE trial was completed with more than 360 patients randomized, with topline data expected in mid-2027. After the quarter, Vicore’s American Depositary Shares began trading on the Nasdaq Capital Market under ticker VCRE, complementing its Nasdaq Stockholm listing.
Net revenues for April–June 2026 were SEK 2.2 million (USD 0.2 million). The company reported an operating loss of SEK 150.1 million (USD 16.0 million) and a loss for the period of SEK 142.8 million (USD 15.3 million), with loss per share of SEK 0.51 (USD 0.05). Research and development expenses represented 78.0% of operating expenses, underscoring the R&D focus.
Equity at June 30, 2026 was SEK 853.6 million (USD 87.7 million). Cash, cash equivalents, and short-term investments totaled SEK 905.6 million (USD 93.0 million), with cash flows used in operating activities of SEK 155.9 million (USD 16.7 million) in the quarter. Management states this supports a cash runway extending into the second half of 2028, providing visibility through the ASPIRE readout.
Vicore Pharma Holding has appointed Rob Slack, PhD, FRSB as Chief Scientific Officer, succeeding Johan Raud, MD, PhD, who will transition to Senior Advisor. Dr. Slack brings over 20 years of leadership in fibrosis and respiratory translational science, including senior roles at GSK as Vice President and Head of Respiratory Biology and prior service as acting Chief Scientific Officer at Galecto. He has contributed to multiple approved respiratory medicines for asthma, COPD and IPF and has more than 60 scientific publications. As Chief Scientific Officer, he will lead Vicore’s research strategy and development of its next-generation angiotensin II type 2 receptor agonist pipeline, including the lead program buloxibutid, which is in a global 52‑week Phase 2b ASPIRE trial in idiopathic pulmonary fibrosis and holds Orphan Drug and Fast Track designations from the U.S. FDA.